RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Jafron Biomedical Co Stock

Jafron Biomedical Co Revenue 2025

Jafron Biomedical Co Revenue

2.97 B CNY

Ticker

300529.SZ

ISIN

CNE100002995

In 2025, Jafron Biomedical Co's sales reached 2.97 B CNY, a 10.86% difference from the 2.68 B CNY sales recorded in the previous year.

The Jafron Biomedical Co Revenue history

YEARREVENUE (B CNY)GROSS MARGIN (%)
2027e4.0253,69
2026e3.4562,58
2025e2.9772,68
20242.6880,57
20231.9279,95
20222.4982,32
20212.6884,97
20201.9585,24
20191.4386,21
20181.0284,80
20170.7284,15
20160.5483,94
20150.5184,54
20140.3784,71
20130.383,70

Jafron Biomedical Co Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Jafron Biomedical Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Jafron Biomedical Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Jafron Biomedical Co’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Jafron Biomedical Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Jafron Biomedical Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Jafron Biomedical Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Jafron Biomedical Co’s growth potential.

Jafron Biomedical Co Revenue, EBIT and net profit per share

DateJafron Biomedical Co RevenueJafron Biomedical Co EBITJafron Biomedical Co Net Income
2027e4.02 B undefined0 undefined1.3 B undefined
2026e3.45 B undefined2.08 B undefined1.09 B undefined
2025e2.97 B undefined1.62 B undefined907.1 M undefined
20242.68 B undefined1.04 B undefined820.2 M undefined
20231.92 B undefined529 M undefined436.49 M undefined
20222.49 B undefined1.01 B undefined889.54 M undefined
20212.68 B undefined1.37 B undefined1.2 B undefined
20201.95 B undefined1.01 B undefined875.2 M undefined
20191.43 B undefined636.1 M undefined570.8 M undefined
20181.02 B undefined432.3 M undefined402 M undefined
2017718.5 M undefined286.7 M undefined284.4 M undefined
2016543.6 M undefined225.7 M undefined202.1 M undefined
2015508.9 M undefined226.8 M undefined200.4 M undefined
2014370.9 M undefined169 M undefined160 M undefined
2013303.6 M undefined140.1 M undefined126.8 M undefined

Jafron Biomedical Co stock margins

The Jafron Biomedical Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Jafron Biomedical Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Jafron Biomedical Co.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Jafron Biomedical Co's sales revenue. A higher gross margin percentage indicates that the Jafron Biomedical Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Jafron Biomedical Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Jafron Biomedical Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Jafron Biomedical Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Jafron Biomedical Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Jafron Biomedical Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Jafron Biomedical Co Margin History

Jafron Biomedical Co Gross marginJafron Biomedical Co Profit marginJafron Biomedical Co EBIT marginJafron Biomedical Co Profit margin
2027e80.57 %0 %32.26 %
2026e80.57 %60.28 %31.57 %
2025e80.57 %54.55 %30.56 %
202480.57 %38.69 %30.63 %
202379.95 %27.52 %22.71 %
202282.32 %40.38 %35.7 %
202184.97 %51.21 %44.73 %
202085.24 %51.81 %44.86 %
201986.21 %44.43 %39.87 %
201884.8 %42.53 %39.55 %
201784.15 %39.9 %39.58 %
201683.94 %41.52 %37.18 %
201584.54 %44.57 %39.38 %
201484.71 %45.56 %43.14 %
201383.7 %46.15 %41.77 %

Jafron Biomedical Co Aktienanalyse

What does Jafron Biomedical Co do?

Jafron Biomedical Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Jafron Biomedical Co's Sales Figures

The sales figures of Jafron Biomedical Co originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Jafron Biomedical Co’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Jafron Biomedical Co's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Jafron Biomedical Co’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Jafron Biomedical Co stock

How much revenue did Jafron Biomedical Co generate this year?

Jafron Biomedical Co has achieved a revenue of 2.97 B CNY this year.

How much was the turnover of the company Jafron Biomedical Co compared to the previous year?

The revenue of Jafron Biomedical Co has increased by 10.86% increased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Jafron Biomedical Co?

The revenue of Jafron Biomedical Co is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Jafron Biomedical Co measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Jafron Biomedical Co so important for investors?

The revenue of Jafron Biomedical Co is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Jafron Biomedical Co pay?

Over the past 12 months, Jafron Biomedical Co paid a dividend of 0.4 CNY . This corresponds to a dividend yield of about 1.65 %. For the coming 12 months, Jafron Biomedical Co is expected to pay a dividend of 0.84 CNY.

What is the dividend yield of Jafron Biomedical Co?

The current dividend yield of Jafron Biomedical Co is 1.65 %.

When does Jafron Biomedical Co pay dividends?

Jafron Biomedical Co pays a quarterly dividend. This is distributed in the months of July, June, June, June.

How secure is the dividend of Jafron Biomedical Co?

Jafron Biomedical Co paid dividends every year for the past 11 years.

What is the dividend of Jafron Biomedical Co?

For the upcoming 12 months, dividends amounting to 0.84 CNY are expected. This corresponds to a dividend yield of 3.58 %.

In which sector is Jafron Biomedical Co located?

Jafron Biomedical Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Jafron Biomedical Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Jafron Biomedical Co from 5/26/2025 amounting to 0.8 CNY, you needed to have the stock in your portfolio before the ex-date on 5/26/2025.

When did Jafron Biomedical Co pay the last dividend?

The last dividend was paid out on 5/26/2025.

What was the dividend of Jafron Biomedical Co in the year 2024?

In the year 2024, Jafron Biomedical Co distributed 0.67 CNY as dividends.

In which currency does Jafron Biomedical Co pay out the dividend?

The dividends of Jafron Biomedical Co are distributed in CNY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Jafron Biomedical Co

Our stock analysis for Jafron Biomedical Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Jafron Biomedical Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.